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A B S T R A C T
 
 
 
Transdermal biotechnologies are an ever increasing ﬁeld of interest, due to the medical and pharmaceutical applications that they underlie. There are several 
mathematical models at use that permit a more inclusive vision of pure experimental data and even allow practical extrapolation for new dermal diffusion 
methodologies. However, they grasp a complex variety of theories and assumptions that allocate their use for speciﬁc situations. Models based on Fick's First Law 
found better use in contexts where scaled particle theory Models would be extensive in time-span but the reciprocal is also true, as context of transdermal 
diffusion of particular active compounds changes. This article reviews extensively the various theoretical methodologies for studying dermic diffusion in the rate 
limiting dermic barrier, the stratum corneum, and systematizes its characteristics, their proper context of application, advantages and limitations, as well as 
future perspectives. 
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1. Introduction 
 
Nanotechonology, whose importance is presently undisputed [1,2] 
represents the avenue and the frontier of Biotechnology and Biomedical 
Engineering. Among many of the possible new solutions, the    ones 
 
 
 
 
 
 
 
 
 
 
regarding disadvantages of current biomedical devices that increase 
transport across the skin, such as microneedles [2,3], are of particular in- 
terest in transdermal applications. At present, microneedles, a device 
that may provide a more efﬁcient transdermal drug delivery, are an ex- 
ample of a larger research area: dermic diffusion. The microneedle 
piercing increases the skin permeability of the variety of compounds 
ranging from low molecular weight tracers to proteins, DNA and even 
nanoparticles [4,5]. However, the trauma suffered by the  patients 
is still an issue, and a nanoneedle could prevent such problems, 
since there are studies relating positively the narrowness of the needle 
size and the minimization of trauma [6]. The common option of 
microneedles in many transdermal applications, despite the above- 
mentioned issues, lies in the difﬁculty to diffuse the compounds through 
the skin, especially through the stratum corneum [7,8]. Understanding 
this speciﬁc diffusion means understanding the ground that sustains 
drug delivery method's evolution. However, it is difﬁcult, if not impossi- 
ble in some cases, to determine experimentally the nanoidiosyncrasies 
at molecular level that explain the sustainability of the material and/or 
device at macroscopic level. Furthermore, the apprehension at molecu- 
lar level of the material's nature and chemical reactivity would permit 
extrapolation for other scenarios and even new materials. The impor- 
tance of theoretical models, thus, is increasingly paramount not only 
for the present micro technologies but also for the future achievements 
in the nanoresearch. 
Nevertheless, the elaboration of such models faces the complexity of 
the dermic barrier. To study such surface implies a large number of indi- 
vidual fragments, each one with a unique nano chemical composition. 
The skin layer that presents the ﬁrst barrier in dermic diffusion is the 
stratum corneum (SC), just 15 to 20 μm thick, and is constituted by dif- 
ferentiated keratinocytes embedded in lipid layers [3]. Not only is the 
SC complex in merely chemical constitution but also its organization, 
an inherent aspect of the identity of the SC [7], adds to the difﬁculty of 
modelling the barrier. Diffusion models usually focus on the SC since, 
though it is the thinnest layer at most locations of diffusion interest, it 
presents the highest resistance to transport and is, therefore, rate limit- 
ing for most solutes [8,9]. Beneath the SC is the location of the epider- 
mis, which thickness ranges from 130 to 180 μm and ﬁnally, as one 
penetrates the skin, one founds the dermis, ﬁlled with complex struc- 
tures such as the nerves, blood vessels, nociceptors, lymph vessels, 
hair follicles and sweat glands [10,11], as schematized in Fig. 1. The 
dense multilayered nature of dermic barrier, thus, complicates the 
(trans) dermal drug delivery, even when the administration is by sim- 
ply piercing through the skin. This explains why the majority of 
(trans) dermal products in the market are low molecular-weight 
drugs with high potency [12–14]. 
This article aims to comprehensively review the diffusion mathe- 
matical models through the SC. Though active particles may be deliv- 
ered through other processes, diffusion is considered to be the 
essential process of drug transport via the SC, if not even the primary 
 
 
 
Fig. 1. Stratum corneum. 
 
[8,9]. Thus, we will not consider any other transdermic drug transport, 
which has been reviewed elsewhere [15,16]. The following processes 
exemplify the potential applications of transdermal diffusion mathe- 
matical models, in view of the many experimental limitations at 
present. 
 
2. Transdermal applications 
 
Transdermal application is a route of administration wherein active 
compounds are delivered across the skin for systemic distribution. Al- 
though the skin is a large and logical target for drug delivery, its basic 
functions, as a protective barrier against external pervasive agents, 
limit its utility. Therefore, understanding the barrier's functions and 
namely its ﬂexibility, provides the basis of applications, as described 
below. 
 
2.1. Diffusion of active compounds 
 
Drug delivery through the skin has multiple beneﬁts over both oral 
route and conventional injections, although the dense structure of the 
stratum corneum and the limited number of hair follicles and sebaceous 
glands complicates the delivery of therapeutic doses [2]. 
The dermis and the overlying epidermis compose the skin. The out- 
ermost layer of the epidermis is the stratum corneum, comprised of a 
multi-layered structures of keratinocytes embedded in a matrix of hy- 
drophobic lipids organized into tight lamellar structures [17,18]. The 
dermis contains a network of capillaries that connect to the systemic 
circulation and if a drug penetrates the stratum corneum, then it can 
readily reach the dermis and enter the bloodstream by passive diffusion. 
Diffusion is considered the rate-limiting step for the transdermal trans- 
port of drug molecules, through the delivery of molecules into and 
across the skin and depends on the substance's physicochemical 
properties. 
The particles, which are described to have a better drug delivery, are 
the nanoparticles. They enhance drug absorption allowing sustained 
drug release for a prolonged period of time and protecting the capsulat- 
ed substance from chemical degradation. The active compounds can 
enter into the skin by different routes: intercellular pathway, transcellu- 
lar pathway, transappendageal pathway and paradermic pathway. 
Whereas the active compounds enter the skin through the lipid 
extracellular matrix (ECM) in the (1) intercellular pathway, occupying 
the intercellular spaces of the keratinocytes, in the (2) transcellular 
pathway which is through the keratinocytes; ﬁnally, the active 
compounds may also cross along the shafts of hair follicles in the 
(3) transappendageal pathway, through the sebaceous and sweat 
glands that are dispersed all over the skin. Nanocarriers can enter into 
the skin and remain intact or can be degraded near the skin surface 
releasing the active substance to penetrate into the skin layers [18,19]. 
 
2.2. Removal of active compounds/substances 
 
Drug delivery involves a number of circumstances including the 
possibility of extracting the active compounds; one example is the ex- 
traction of glucose and lactate [20,21]. Using transdermal reverse ionto- 
phoresis allows the simultaneous extraction of glucose and lactate from 
human subjects. 
Transdermal monitoring using iontophoresis is made possible by the 
skin's permeability to small molecules and the nanoporous and micro- 
porous nature of the structure of the skin. Reverse iontophoresis refers 
to the passage of a low level of current through the skin, normally via 
a pair of skin electrodes containing a conducting gel, to promote the ex- 
traction of both charged and neutral molecules [20]. 
Ching and collaborators using a nanoporous membrane as the skin- 
like barrier in the iontophoresis cell with and without application of ion- 
tophoretic current performed in vitro diffusion studies. This showed that 
passage of a current facilitates movement of lactate and glucose across 
  
 
the nanoporous membrane when compared to ordinary diffusion; and 
during the studies, lactate and glucose were extracted successfully 
using reverse iontophoresis [21]. 
 
2.3. Dermal reconstruction/skin regeneration 
 
Dermal reconstruction is a complex process, which involves many 
cells, such as epidermal, ﬁbroblastic, and endothelial cells, and various 
processes such as proliferation, cell migration, matrix synthesis, and 
contraction. Wound healing is a complex and dynamic process of restor- 
ing cellular structures and tissue layers which progresses in an arranged 
and conventional fashion such as inﬂammation (reactive), proliferation 
(regenerative) and maturation (remodelling) [22]. 
When the skin is breached, initially there is the laying down of a 
ﬁbrin blood clot, which plugs the defect and seals off the underlying 
tissues from oxygen in the air. The degenerating platelet secretes 
platelet-derived growth factor (PDGF) and stimulates the ﬁrst phase 
of cell proliferation of epidermal cells, ﬁbroblasts and endothelial cells. 
Then, neutrophils arrive at the wound site and clear out debris and con- 
taminating bacteria and secrete proinﬂammatory cytokines, which acti- 
vate local ﬁbroblasts and keratinocytes. Past few days, the blood-borne 
macrophages replace the neutrophils and they produce cytokines and 
Fick's First Law. The fraction that is absorbed in speciﬁc period of time 
is constant and will remain constant at different concentrations [32,34]. 
Let us consider that Q is the amount of solute, i.e., the amount of sub- 
stance that will ﬂow in a small interval of time through a small surface. If 
we consider the small surface, A, as the skin membrane where the diffu- 
sion occurs, over a period of time t, through the path length h (the thick- 
ness of the skin membrane), due to the concentration gradient across 
the two interior surfaces of the skin, ∇Cs then the relation between Q 
and the diffusion's coefﬁcient in the skin membrane, D, is of direct pro- 
portional and is given by Fick's First Law, describing skin transport 
under steady-state conditions [38]: 
 
 
 
 
This approach assumes that dermal absorption is a ﬁrst order pro- 
cess that can be described according to Fick's First Law of diffusion 
[32]. Stratum corneum behaves like a pseudo-homogenous membrane 
and barrier properties do not vary with time or position. Deﬁning 
steady-state skin ﬂux, Jss as the amount of solute per unit area and per 
unit time, Eq. (1) is rearranged as follows: 
growth factors essential to wound healing. After a week, the wound is 
inﬁltrated by activated ﬁbroblasts, stimulated by TGF-β that increases 
the synthesis of single strands of collagen. Then wound ﬁbroblasts are 
 
  
transformed into myoﬁbroblasts, which express α-smooth muscle 
actin (α-SMA) acquiring the ability to generate strong contractile forces. 
The proliferation of myoﬁbroblasts results in the formation of scar tissue 
[23]. 
Whereby, the maximum ﬂux, Jmax, is given when the maximum 
solubility Ss of a solute in the stratum corneum is achieved, and the equa- 
tion can be written as [30,36]. 
 
 
3. Dermic diffusion and mathematical models: a review  
  
Traditionally, the skin, the SC and the diffusion phenomena have 
been studied associated with pure mathematical models, especially 
based on the Fick Equation [24–32]. A systematic analysis of these 
models implies a division based upon the particular approach and use 
of the Fick Law. However particular views in speciﬁc devices have raised 
new challenges and other mathematical models were developed. An 
extensive review of these models was made and the relevant synthesis 
is presented in Table 1. 
The mathematical models that approach the skin at nano level can 
 
The thermodynamic activity for any given solute is deﬁned by 
the fractional solubility of the solute in the skin (Cs/Ss). However, 
nonlinearity can arise as a result of solute-skin and solute–vehicle 
non-ideal interactions [30,37]. It is (Cv) more convenient to express 
concentrations in terms of the solute concentration in the vehicle 
and a partition coefﬁcient, K, of the solute between the skin and the 
vehicle as follows: 
 
 
be classiﬁed according to the methodological assumptions, i.e., they 
are either based on the Fick's First Law, the Laplace transform, the scaled 
particle theory, the homogeneous membrane model or hybrid approach 
(using the First and the Second Law of Fick). Thus, analysing each model 
implies an analysis of the particular approach chosen and the reasons 
for such choice. Also, it is important to understand the boundary condi-  
 
tions in these models. Boundary conditions are the physical restraints in 
the mathematical model, limiting the solution-space of the equations. 
 
3.1. Fick's First Law 
 
When a drug is placed on the skin surface, it migrates to the inner- 
most layers through the stratum corneum and viable epidermis  [29]. 
 
 
 
The assessment of permeability coefﬁcient (Kp), has been the main 
focus of the permeation model. Kp, is deﬁned as the steady-state ﬂux 
of chemical across the skin (Jss) normalized by the concentration gradi- 
ent, Cv: 
 
Stratum corneum, as depicted in Fig. 1, is composed by keratinocytes 
which becomes a substantial barrier to drug delivery because active 
and facilitated transport is difﬁcult in delivering drug [3]. Passive diffu- 
 
  
sion is a mechanism by which chemicals move through the stratum 
corneum, as can be seen in Fig. 3 [32]. 
Fick's Laws of diffusion determines that diffusion occurs in favour of 
the concentration gradient, in others words, it occurs in the direction 
from higher to lower concentration [32,33]. This principle is applied in re- 
cent mathematical models used to describe the dermal absorption 
through the stratum corneum [32,34,35]. The stratum corneum lipid ma- 
trix is viewed as a homogeneous medium surrounding keratinocytes 
where a substance diffuses from high to low concentration according to 
The understanding of percutaneous penetration is best exempliﬁed 
in models that are underpinned by experiment. For example, the 
concentration proﬁles in the skin have been examined to separate the 
effects of the partition coefﬁcient and the diffusion on permeation 
[38]. Furthermore, mathematical models provide means to assess 
the likelihood of systemic exposure upon dermal contact with toxic 
chemicals. Mitragotri and collaborators have been applied of mathe- 
matical modelling to dermal risk assessment, privileging the use of 
permeability coefﬁcients (Kp) and their model-based estimation [30]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.1. Fick's First Law and passive diffusion models 
Models of passive diffusion are based on particle number 
conservation and diffusion Fick's Laws. Some reported mathe- 
matical approaches reported are based on diffusion models that 
consist in partial differential equations describing drug  delivery 
in space and time according with diffusion Fick's Laws [31]. 
According to diffusion Fick's Laws, penetrants are transported, 
through the skin, via the transcellular, intercellular and trans- 
appendageal routes [18,28,39]. These different transports are 
depicted in Fig.  2. 
  
 
difference across the barrier (in g/mL units), then TEWL is directly pro- 
portionate to the water concentration difference across the barrier: 
   
 
 
 
The combined parameter KP  = (K.D) / H, is the permeability coefﬁ- 
cient. Determination of H, D and KP comes from: (1) knowledge or as- 
sumption of K, and (2) construction of a plot of 1/TEWL(x)  versus X, 
where X (in μm units) is part of the stratum corneum removed by tape 
stripping, resulting in TEWL increasing to TEWL(x)  [40,41]. The equa- 
tions used in the plot analysis are: 
  
 
 
 
 
 
TEWL increased slowly at ﬁrst and then more rapidly with the de- 
gree of stratum corneum impairment. Secondly, low-frequency skin im- 
pedance decreased exponentially as a function of progressive stratum 
corneum removal. The differential sensitivities of TEWL and low- 
frequency impedance measurements to the degree of barrier impair- 
ment suggest that the techniques used together represent a way to 
characterize stratum corneum functionality [40]. 
 
3.2. Fick's Second  Law 
 
Fig. 2. Schematic presentation of the routes for permeation of the agent applied. 
 
 
 
 
Regarding the studies of Mitragotri and collaborators, the transport 
processes in the skin can be described by Fick's First Law [30]. Further- 
more, Higuchi and team derived mathematical models that describe 
percutaneous absorption as a passive diffusion process in the vehicle 
and the membrane layers in series [36]. 
Sekkat and collaborators evaluated the biophysical properties, such 
as transepidermal water loss (TEWL) of porcine ear skin and compared 
the results with data from the human skin in vivo [40]. Using Fick's First 
Law of diffusion to describe TEWL across the skin, if K is the stratum 
corneum/water partition coefﬁcient, D is the diffusivity of water across 
Other mathematical models describing the delivery of drug through 
the dermis are based on Fick's Second Law. While Fick's First Law 
assumes steady state, Fick's Second Law predicts the concentration 
gradient changes, through diffusion, with time. Any dermic diffused 
drug is placed on the skin surface and travels to the innermost layer 
through the stratum corneum and viable epidermis, as previously seen. 
One can locate the origin of the delivery process at the interface 
between these two regions [29]. 
According Fick's Second Law of diffusion, to estimate the concentra- 
tion of the drug along a perpendicular axis to the membrane, designed 
normally by u(t,x), [24,25,29], where x is the thickness of the membrane 
and t is the period of time, it must be found the solution of following 
linear one-dimensional diffusion equation: 
the stratum corneum of thickness H, and ΔC is the water concentration  
  
where the thickness varies from null to a maximum, L, corresponding to 
the maximum value of the membrane thickness. The delivery rate or 
ﬂux, j, is deﬁned by: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Passive diffusion mechanism. 
 
 
In addition to physical methods, drug permeation through the 
stratum corneum can use chemical penetration enhancers [25,42,43]. 
Cis-9-Octadecenoic acid (oleic acid, OA) was found to be a good pene- 
tration enhancer [25,44,45], and research regarding the impact of the 
penetration enhancer, oleic acid, on the barrier properties of stratum 
corneum lipid model membranes was conducted. 
The Second Law was studied using a two lipid model membranes 
(membrane I and membrane II) with incorporated oleic acid. The compo- 
sition of the membranes is summarized in Table 2, and was characterized 
the impact of their composition on the barrier function by conducting dif- 
fusion and permeation studies of three model molecules (urea, caffeine 
and diclofenac sodium). 
The study showed that the presence of oleic acid weakened the 
barrier function of membrane I and demonstrated the opposite effect 
A 
Table 2 
Composition of SC lipid model membranes. 
  
 
Model membrane Composition 
 
Membrane I Cer [AP]/Chol/PA/ChS 
Membrane II Cer [AP]/Cer [EOS]/Chol/PA 
Membrane Ia Cer [AP]/Chol/PA/ChS/OA 
Membrane IIa Cer [AP]/Cer [EOS]/Chol/PA/OA 
 
  
 
 
 
 
on membrane II. In the presence of the penetration enhancer the diffu- 
sion and permeation of model molecules were more rapid than for the 
stratum corneum Lipid Model Membrane without oleic acid. 
Previous studies showed that: (1) the diffusion of urea was faster 
than the permeation of caffeine and diclofenac sodium; (2) urea, the 
most hydrophilic drug, diffused faster than caffeine, the more lipophilic 
molecule; and (3) urea is even faster than the most lipophilic drug, 
diclofenac sodium [25]. 
Several authors used a model based on Fick's Second Law of diffusion 
to calculate the diffusion coefﬁcient of model drugs. Thus, the drug con- 
centration, u(t,x), within the model membrane can be approximated by 
a solution of linear one-dimensional diffusion equation, as mentioned 
before [24,25]. 
 
3.2.1. Fick's Second Law and passive diffusion models 
The Fickian diffusion model is also applied in studies regarding the 
use of transdermal patch with multi-layer, planar, drug-in-polymer 
adhesive patch applied to the skin, where each layer contains a different 
concentration of drug encapsulated in the polymer matrix. It can also be 
seen in cases where the systems are represented by a vehicle, a skin 
membrane and a capillary [28]. In this model, drug concentrations in 
the vehicle, C1, and skin, C2, are different, as are the effective drug diffu- 
sions on the vehicle and the skin, respectively; D1 and D2. 
Simon and team have dedicated efforts to study the transport of a 
medicinal agent through the vehicle and subsequent penetration into 
the stratum corneum [28]. Eigenmodes and eigenvalues were computed 
and introduced into an inversion formula to estimate the delivery rate 
and the amount of drug in the vehicle and the skin. The calculations 
were obtained using Mathematica® (Wolfram Research, Inc.), a com- 
puter software. 
It was observed that repeated applications of a ﬁxed dose lead to an 
accumulation of drug in the skin. This accumulation is counterbalanced 
by an increase in the ﬂux of the drug to the receptor site [28,46]. A 
plateau is reached when the rates of absorption and elimination are 
equal. This technique can be applied to estimate the dose-loading 
necessary to achieve a speciﬁed release rate. A constant plasma drug 
concentration is obtained by increasing the application period and/or 
reducing the removal period which produce a more continuous drug 
delivery [28]. 
 
3.3. Hybrid approach: ﬁrst and second Law of Fick 
 
As previously mentioned, current mathematical models use the 
Fick's Law of diffusion to describe dermal absorption through the 
stratum corneum [32,34,35]. Chemicals, in the stratum corneum lipid 
matrix, diffuse from high to low concentration according to Fick's First 
Law. The fraction of a chemical dose that is absorbed through the skin 
over a speciﬁed period of time is constant, and will remain constant at 
various concentrations of chemical applied in the skin surface. 
Schumm and collaborators [32] propose another approach to the 
  
  
mathematical modelling of the chemical kinetics in the stratum corneum 
lipid matrix. They represented the lipid structure as a network where 
the lipid regions are represented as nodes and used the following  ∂C 1   ∂  C 1  
  
The thicknesses of the vehicle, a, and of the skin, b, are part of the ini- 
tial conditions of Eqs. (11) and (12). Let C10 be the initial drug concentra- 
tion in the vehicle and C20 be the initial drug concentration in the skin for 
the ﬁrst application, both in μg/cm3. Then the initial conditions are: 
  
 
 
  
 
The boundary conditions are represented by Eqs. (15), (16), (17) 
and (18). Considering that Km  is the patch-skin partition coefﬁcient, 
models to describe the process by which solute transfers between two 
adjacent nodes, based on Fick's Law. 
The ﬁrst model is designed to have a linear solute transfer. To node A 
with NA molecules, a fraction of its molecule will be at the A–B interface 
during each time interval as a function of the relative interface sizes and 
the diffusivity of the solute. Consider that NA is the molecules in node A, 
dNiA is the number of solute molecules within node A migrating to the 
interface of nodes A and B, during the time interval dt SAB is the surface 
area shared by nodes A and B, SAtot is the total surface area of node A, D is 
the solute diffusivity in node A, and R2 is the radius of the region repre- 
sented by node A. Then the fraction of molecules at the A–B interface 
during each time interval is a function of the relative interface sizes 
and the diffusity of the solute: 
Kcl   is deﬁned as the clearance per unit area of the medicament   per 
 
:  
 
unit concentration excess at x = b, T is the application period, and 
that the transport is done in the direction perpendicular to the skin 
surface, the Eq. (15) states that no exchange of material occurs between 
the vehicle and the surrounding, while Eq. (16) imposes the continuity 
of ﬂux across the vehicle/skin interface, Eq. (17) corresponds to an equi- 
librium condition at the vehicle/skin interface and Eq. (18) states that 
elimination of drug by capillary system follows ﬁrst-order kinetics at 
x = b. [28,46]. 
 
 
 
 
 
 
The molecules in node A at the interface of node A with B will 
partition to node B if they have sufﬁcient energy to cross the node bound- 
ary. The Maxwell–Boltzmann distribution (exempliﬁed in Fig. 4) charac- 
terizes the energy of a group of molecules. The molecules with higher 
energies will be on the right side of the distributions and the lower ener- 
gy will be on the left. 
The total area under the distribution is the number of solute mole- 
cules in node A. 
 
 ð20Þ 
  
 
Fig. 4. Maxwell–Boltzmann distribution: LE, Low energy molecules; HE, High energy 
molecules; KA(B), solubility of node A (B); α, upper limit of integration for NA; V1, upper 
limit integration for LE. 
 
 
 
The molecules that partition from node A to node B are the mole- 
cules at the A–B interface sufﬁcient energy to cross the node boundary. 
of systems: reservoir system and monolithic systems, as illustrated by 
Fig. 5. The reservoir system is surrounded by a release rate controlling 
barrier membrane. In the monolithic system there is no local separation 
between a drug reservoir and the release rate controlling barrier [26]. 
In the reservoir device, if initial drug concentration is below drug 
solubility, released drug molecules are not replaced and the drug con- 
centration at the inner membrane's surface decrease with time. Still, if 
the initial drug concentration is higher than the drug solubility, release 
molecules are replaced by the (partial) dissolution of drug crystal/ 
amorphous aggregates, resulting in constant drug concentrations at 
the inner membrane's surface. In the monolithic device, the system 
geometry has inﬂuence on the resulting drug release kinetics. If the 
initial concentration is below drug solubility, the drug molecules are 
dissolved within the carrier material. If not, dissolved drug molecules 
coexist with amorphous aggregates and/or drug crystals [26,47]. 
 
3.4. Laplace transform 
 
 
  
The expression of the transport of a solute through the skin involves 
 
 
 
a number of steps in a space and time variant process that it is not easy. 
It is not straightforward to describe the process in a single equation due 
The solute level of node A is then update with the net difference of 
the transfer between nodes A and B. 
to the complexity of the equations [30]. Laplace transform can be used 
to describe skin permeation of drug and metabolite, admitting ﬁrst 
order kinetics. 
 
 
  
  
Laplace transform is an integral transformation used to  resolve 
ordinary and partial differential equations [25,30,31,48,49]. Laplace 
transform is deﬁned by: 
The second model is designed to increase solute transfer from nodes 
with a high to low solute concentration to low concentrations. Higher 
solute concentrations cause physical–chemical changes in the lipid 
matrix that decrease its barrier properties. When the quantify A is greater 
 
than B, diffusivity in A will be greater than diffusivity in B. The difference 
induces a gradient increasing the transfer from node A to node B. And the 
third model is designed to enforce a node capacity and allow only a ﬁnite 
amount of solute in a node at any given time [32]. This model calculates 
the fraction y to transfer from node A to node B with the fraction x of 
NB   over  NBmax. 
where Lis the Laplace operator, s is the Laplace variable and the hat over 
the function denotes the Laplace transform. 
Laplace transform reduces the partial differential diffusion equation 
into an ordinary differential equation which is much easier to solve, and 
his way, the Laplace transform of the diffusion equation, where C(x, 0) is 
the initial condition, is as following: 
   
 
 
 
 
  
  
The equation y(x) is given for a rolloff model and an exponential 
model. In the rolloff the transfer as node B reaches its capacity (when 
x tends to 1) and in exponential model exponentially decays the transfer 
as node B reaches its capacity. 
 
If the skin starts out without any chemical, C(x, 0) = 0. Taken that 
into account and considering h to be the thickness of the SC, td = h
2/D 
is the characteristic time of diffusion, and A(s) and B(s) functions  of 
 
 
 
 
 
  
 
 
 
  
Schum and team simulated the basic models over time and differing 
surface solute concentrations and they found that any amount of solute 
in node A is the same fraction of the solute transferred to node B, which 
mimics Fickian diffusion. They also found that when the transference of 
solute through all nodes is integrated, the fraction of solute transferred 
remains constant across a range of doses, which also resembles Fickian 
diffusion. Higher node capacities result in higher solute transfer rates 
[32]. 
Furthermore, Siepmann and collaborators mentioned several 
theories based on diffusion Fick's Law, and conclude that the mathemat- 
ical treatment can be rather straightforward, if drug release is controlled 
with constant diffusion coefﬁcients [26]. They distinguished two types 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Representation of reservoir and monolithic system. 
sc 
sc 
 
only s, only determined from boundary conditions, the above equation 
presents the following general solution: 
0.4 to 0.9 depending on the data set used in the regression. 
  
 
For estimating KSC/v were derived expressions that consider the indi- 
 
Also, h 
can be further manipulated to calculate the transdermal ﬂux and 
cumulative drug transport [30,50–52]. 
Simon and collaborators indicated that the equations of drug delivery 
can be solved using the Laplace transform [29]. The Laplace transform- 
based solution strategy was chosen due to the direct calculation of an 
effective time constant. This time constant is the time it takes to achieve 
a desired release rate and steady-state concentrations in the skin. 
Roberts and team also considered the kinetics associated with the 
reservoir effect of the stratum corneum [37]. As the fraction unbound is 
less than unity, the link leads to a slower diffusion. If binding/partitioning 
is not fast compared to diffusion, the single diffusion equation has to be 
replaced by coupled partial differential equations: 
vidual contributions of the lipid and keratinocytes [30,56]: 
 
  
where Klip/v is the lipid–vehicle partition coefﬁcient, Kcor/v is the 
keratinocytes–vehicle partition coefﬁcient, and ϕlip and ϕcor are the 
volume fractions of lipid and keratinocytes in the stratum corneum, 
respectively, which together sum to 1. 
Scaled particle theory has been used to simplify utilization of molec- 
ular details of structures in predicting skin permeability [57]. There are 
two factors solute partitioning into lipid bilayers. They are the chemical 
and physical factors. In the chemical factor, lipid bilayer is more hydro- 
phobic than the surrounding aqueous conditions. In the physical factor, 
lipid chains in the bilayer are highly organized, thus reducing the parti- 
 tion coefﬁcient [30,58,59]. 
 
  
where Cb and Cu 
are the concentrations of bound and unbound solutes, D is the diffusion 
coefﬁcient if the unbound solute (bound solute is assumed immobile, or 
its diffusion is so slow that it can be neglected) and Kon and Koff  are the 
binding and unbinding rate constants. 
Taking Laplace transform of these equations and expression of C̈b 
using C̈u  yields: 
The theory showed that the partition coefﬁcient of a solute from 
water into stratum corneum lipid matrix is comparable to that into an 
isotropic solvent. Thus scaled particle theory reasonably mimics the 
chemical environment in the stratum corneum lipid matrix. Several sol- 
vents have been used as model for stratum corneum lipids (octanol, 
hexadecane, olive oil, butadiene and dodecadiene). The most conve- 
nient seems to be octanol [30,56,60–65]. 
Mitragotri and collaborators also used this theory. They developed 
an equation to describe solute diffusion in lipid bilayers. The theory 
calculates diffusion coefﬁcient based on the amount of work required 
creating a free volume to allow for solute diffusion [30]. 
 D   
  : 3.6. Homogeneous membrane model 
  
    
The geometry of the stratum corneum and the detailed arrangement 
of both keratinocytes and lipids make a great deal of difference in model 
The only difference between simple diffusion equation in the Laplace 
domain is that s is replaced by a function g(s), where: 
 
calculations, as it affects the path length for diffusion, making the lipid 
tortuosity factor be of great importance [63,66,67]. However, since 
diffusion is primarily transcellular, then the lipid tortuosity factor is of 
the secondary importance. Also, as the keratinocytes-phase transport 
 
  
reduces, the impact of lipid tortuosity increases [30]. 
Frasch and Barbero studied transient diffusion through model struc- 
Thus equations for the unbound concentration and ﬂux through 
stratum corneum can be obtained by replacing s with g(s) in the above 
equations [30,53]. 
Hallmark studies of Hadgraft and collaborators [50,51] and Guy and 
Hadgraft [52] make them the pioneers in the use of Laplace transform 
for mathematical modelling of skin transport. Recently Anissimov and 
Roberts [53] following these ideas used the numerical inversion of 
Laplace transform solutions to the diffusion equation for simulations 
and data analysis of skin transport experiments. Bando et al. [54,55] 
developed a two-layer diffusion model which incorporates both polar 
and non-polar pathways and Laplace transformed equations were 
obtained to describe skin permeation of a drug or substance [30]. 
 
3.5. Scaled particle theory 
 
There are three parameters that are most required to predict skin 
tures of the stratum corneum including both ordered and disordered 
keratinocyte-phases [68]. They found that diffusion was well described 
by a homogeneous membrane model; nevertheless, the effective diffu- 
sion coefﬁcient, D*, and the effective diffusion path length for the 
ordered structure, h∗ : were different from the input variables [30,68]. 
Deﬁning d as the length, t, as the thickness and g as the space between 
keratinocytes, then h∗ : is given by: 
 
 
 
Though the value of D* was not expressed in such manner, the ﬂux 
and lag time relative are estimated by using of the microscopic ﬂux/lag 
time and by effective ﬂux/lag time [30], and their expressions of the 
ﬂux and lag time relative to a homogeneous membrane, Eqs. (36) and 
(37) respectively, have the same microscopic lipid diffusivity D0 and 
thickness h0: 
permeability, the partition coefﬁcient, the diffusion coefﬁcient and the  
path length. The partition coefﬁcient involves partitioning  between   
 
 
multiple phases; the stratum corneum lipid matrix and the vehicle, the 
keratinocytes and the vehicle, the lipids and the keratinocytes, and be- 
tween the stratum corneum and deeper skin layers. The partition coefﬁ- 
 
 
    
 
cient between the stratum corneum and the vehicle is estimated from   
!
 
structure–activity algorithms relating experimental measurements, 
     
   
where a has been reported to be close to 1, while b varies from about  
  
sc 
 
 
 
 
Fig. 6. Schematic diagram for the ordered structure: h∗ , effective diffusion path length for 
the ordered structure; d, dS and dL, length; t, thickness; g and s, space between 
keratinocytes. 
 
 
 
 
 
where ∝ = d/t is the keratinocyte aspect ratio, represented by dividing 
the length (d) by the thickness (t) of the keratinocytes, and w = dL/ds is 
the offset ratio. Regarding σ and Φ, they relate several variables in the 
ordered structure (depicted in Fig. 6):  σ = s/t,  ϕ = t/(t + g). 
Eqs. (35) and (37) were been validated for isotropic lipids and imper- 
meable keratinocyte [68]. 
 
4. Conclusion 
 
The theoretical models are very important when we are facing 
nanoresearch and micro research. The mathematical modelling of the 
skin has made notable progress in the last decades. Due to the advances 
in information technology the accuracy of these models steadily in- 
creases and they become easier to apply. It would be more favourable 
to use a single general theory applicable to any type of drug delivery sys- 
tem; however, there is a broad spectrum of different mathematical 
models, applicable to speciﬁc types of devices differing in geometry, 
drug and excipient type. 
Fick's Law uses the concept of the passive diffusion to describe the 
drug delivery through the skin. The drug enters to the innermost layers 
of the skin through passive diffusion and this concept is the main prin- 
ciple used in the mathematical models. 
The skin permeability is described by three parameters: partition 
coefﬁcient, diffusion coefﬁcient and path length. The ﬁrst involve 
partitioning between multiple phases: stratum corneum and vehicle, 
lipids, keratinocytes, and among others. The partitioning coefﬁcient is 
also called by permeability coefﬁcient and its estimate through mathe- 
matical models can be used to predict the mass of drug that penetrates 
the skin from a given exposure. Several studies have reported the appli- 
cation of mathematical modelling for estimating permeability coefﬁ- 
cient to calculate systemic uptake. 
Two major challenges lay ahead in theoretical transdermal research. 
A ﬁrst major challenge would be to combine the mathematical theories 
with models quantifying drug transport in the living organism, includ- 
ing drug distribution in the various organs and even within the different 
cell compartments. The second major challenge regards achieving a 
computational skin model that may validate molecular principles in 
dermic diffusion as a foreground of future devices. 
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